SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

10 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

09 Aug 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

27 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update

16 May 2022 15:05:01 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conferences

11 May 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022

09 May 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

03 May 2022 06:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases

21 Apr 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine

06 Apr 2022 16:31:32 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update

31 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022

17 Mar 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting

16 Feb 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

19 Jan 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720

04 Jan 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

03 Jan 2022 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming Investor Conferences

17 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update

10 Nov 2021 15:05:03 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

03 Nov 2021 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

28 Oct 2021 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

12 Oct 2021 07:05:00 By Nasdaq GlobeNewswire